3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
BRCA1/2 Mutation
1
Interventions
Carboplatin
19
Paclitaxel
18
Fluorouracil
16
Cisplatin
16
pembrolizumab
15
Radiotherapy
14
Oxaliplatin
12
Irinotecan
12
Capecitabine
12
Cyclophosphamide
10
Radiation
8
Leucovorin
8
Docetaxel
8
fludarabine
6
Taxes
6
Gemcitabine
6
Trastuzumab
5
fludarabine phosphate
4
aldesleukin
4
LY6K protein, human
4
Fluorodeoxyglucose F18
4
Erlotinib Hydrochloride
4
Bevacizumab
4
spartalizumab
3
Surgical Procedures, Operative
3
S 1 (combination)
3
Pemetrexed
3
Nivolumab
3
Drug Therapy
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Esophageal Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled